11.26
0.55 (5.09%)
Previous Close | 10.72 |
Open | 11.07 |
Volume | 795,329 |
Avg. Volume (3M) | 622,615 |
Market Cap | 658,062,592 |
Price / Earnings (TTM) | 12.65 |
Price / Sales | 0.580 |
52 Weeks Range | |
Earnings Date | 7 Aug 2025 - 11 Aug 2025 |
TTM Dividend Yield | 2.66% |
Profit Margin | 4.89% |
Operating Margin (TTM) | 30.35% |
Diluted EPS (TTM) | 0.890 |
Quarterly Revenue Growth (YOY) | -9.80% |
Quarterly Earnings Growth (YOY) | -18.70% |
Current Ratio (MRQ) | 2.48 |
Operating Cash Flow (TTM) | 51.00 M |
Levered Free Cash Flow (TTM) | -50.65 M |
Return on Assets (TTM) | 2.53% |
Market Trend
Short Term | Medium Term | ||
Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
Medical Instruments & Supplies (Global) | Bearish | Bearish | |
Stock | Embecta Corp. | Bearish | Mixed |
AIStockmoo Score
Analyst Consensus | -0.5 |
Insider Activity | NA |
Price Volatility | 0.5 |
Technical Moving Averages | 2.5 |
Technical Oscillators | 2.0 |
Average | 1.13 |
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States. |
|
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
Investment Style | Small Value |
% Held by Insiders | 0.47% |
% Held by Institutions | 101.37% |
52 Weeks Range | ||
Median | 13.00 (15.45%) | |
Total | 1 Hold |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Mizuho | 23 May 2025 | 13.00 (15.45%) | Hold | 10.72 |
No data within this time range.
Date | Type | Details |
---|---|---|
27 May 2025 | Announcement | embecta to Participate in Investor Events |
22 May 2025 | Announcement | embecta to Showcase Phased Approach for Value Creation and Present Long Range Financial Plan at 2025 Analyst and Investor Day |
09 May 2025 | Announcement | Embecta Corp. Reports Second Quarter Fiscal 2025 Financial Results |
09 May 2025 | Announcement | embecta Announces Quarterly Cash Dividend |
28 Apr 2025 | Announcement | Embecta to host Analyst and Investor Day on May 22, 2025 |
21 Apr 2025 | Announcement | embecta to Report Fiscal Second Quarter 2025 Financial Results |
TTM Dividend Yield | 2.66% |
3Y Average Dividend Yield | 2.49% |
Payout Ratio | 67.42% |
Expected Next Dividend Payment | Sep 2025 |
Ex Date | Announcement Date | Payment Date | Details |
---|---|---|---|
06 Dec 2024 | 26 Nov 2024 | 18 Dec 2024 | 0.15 Cash |
27 Aug 2024 | 09 Aug 2024 | 13 Sep 2024 | 0.15 Cash |
24 May 2024 | 09 May 2024 | 14 Jun 2024 | 0.15 Cash |
27 Feb 2024 | 09 Feb 2024 | 15 Mar 2024 | 0.15 Cash |
01 Dec 2023 | 21 Nov 2023 | 15 Dec 2023 | 0.15 Cash |
24 Aug 2023 | 08 Aug 2023 | 13 Sep 2023 | 0.15 Cash |
25 May 2023 | 12 May 2023 | 13 Jun 2023 | 0.15 Cash |
24 Feb 2023 | 14 Feb 2023 | 13 Mar 2023 | 0.15 Cash |
29 Dec 2022 | 20 Dec 2022 | 11 Jan 2023 | 0.15 Cash |
25 Aug 2022 | 12 Aug 2022 | 14 Sep 2022 | 0.15 Cash |
Annual Dividend Yield
Year | Annual Dividend ($) | Frequency/Year | Yield % |
---|---|---|---|
2024 | 0.600 | 4 | 2.91 |
2023 | 0.750 | 5 | 3.96 |
2022 | 0.150 | 1 | 0.59 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |